RxDoctor Payments Data

Corey Bradley, MD

Cardiovascular Disease · New York, NYNPI 1568825065

Payments from drug & device makers

$993in general payments, 2019–2025

Across 30 payments — averaging $33.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$284
  • Novartis$226
  • Pfizer$210
  • Kiniksa Pharmaceuticals International, PLC$69
  • Esperion Therapeutics, Inc.$50
  • AstraZeneca$49
  • plus $106 from 4 others

What the payments were for

  • Food & beverage$993100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$993 in reported general payments places this provider in the 35th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$86,311
Medicare patients
219
Services billed
3,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$32,966
JardianceEmpagliflozin37$21,374
EntrestoSacubitril/Valsartan27$20,061
Repatha SureclickEvolocumab11$10,350
XareltoRivaroxaban12$6,838
Rosuvastatin Calcium76$1,039
Ezetimibe29$776
Atorvastatin Calcium43$721
Torsemide20$423
Metoprolol Succinate39$410
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide11$289
Amlodipine Besylate30$269
Levothyroxine Sodium16$238
Losartan Potassium31$235
Spironolactone25$146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$210$32,96651 claims
NovartisEntresto$226$20,06127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →